CDK5 and glioblastoma: Inhibitor studies were conducted using selective inhibitors of Cdk5 and GSK3β to understand their contributions to CRMP-2 modulation, enabling the evaluation of how changes in CRMP-2 phosphorylation affected glioblastoma cell proliferation and migration.